health
STAT+: Will Makary’s FDA voucher program survive?
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Even though Rev Med’s&#x A0;experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy. Also, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary could be in for a makeover.Continue to STAT+ to read the full story…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop